Literature DB >> 29773319

Advancements in Nanomedicine for Multiple Myeloma.

Alexandre Detappe1, Mark Bustoros2, Tarek H Mouhieddine2, P Peter Ghoroghchian3.   

Abstract

In the past decades, considerable progress has been made in our understanding and treatment of multiple myeloma. Several challenges remain including our abilities to longitudinally image tumor responses to treatment, to combine various therapeutic agents with different mechanisms of action but with overlapping toxicities, and to efficiently harness the power of the immune system to augment remission and/or to induce permanent cures. Nanomedicine may help to address many of these outstanding issues, affording novel diagnostic capabilities and offering disruptive technologies that promise to revolutionize treatment. Here, we review recent developments and the future of nanomedicine for multiple myeloma, highlighting new considerations in nanoparticle designs that may help to augment active targeting, to facilitate longitudinal imaging, and to improve drug delivery.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  biomarkers; drug delivery; imaging; multiple myeloma; nanomedicine

Mesh:

Year:  2018        PMID: 29773319     DOI: 10.1016/j.molmed.2018.04.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  4 in total

Review 1.  Pathogenesis and treatment of multiple myeloma.

Authors:  Peipei Yang; Ying Qu; Mengyao Wang; Bingyang Chu; Wen Chen; Yuhuan Zheng; Ting Niu; Zhiyong Qian
Journal:  MedComm (2020)       Date:  2022-06-02

2.  LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β-catenin/cyclin D1 signaling via PLAGL2.

Authors:  Qinhua Liu; Ruonan Ran; Mingyue Song; Xiaodan Li; Zhengsheng Wu; Guanrong Dai; Ruixiang Xia
Journal:  Cell Biol Toxicol       Date:  2021-07-31       Impact factor: 6.691

3.  Long non-coding RNA MALAT1 facilitates the tumorigenesis, invasion and glycolysis of multiple myeloma via miR-1271-5p/SOX13 axis.

Authors:  Na Liu; Song Feng; Huanhuan Li; Xiaoguang Chen; Songting Bai; Yufeng Liu
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-18       Impact factor: 4.553

4.  Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.

Authors:  Cinzia Federico; Kinan Alhallak; Jennifer Sun; Kathleen Duncan; Feda Azab; Gail P Sudlow; Pilar de la Puente; Barbara Muz; Vaishali Kapoor; Luna Zhang; Fangzheng Yuan; Matea Markovic; Joseph Kotsybar; Katherine Wasden; Nicole Guenthner; Shannon Gurley; Justin King; Daniel Kohnen; Noha N Salama; Dinesh Thotala; Dennis E Hallahan; Ravi Vij; John F DiPersio; Samuel Achilefu; Abdel Kareem Azab
Journal:  Nat Commun       Date:  2020-11-27       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.